<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943107</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0287</org_study_id>
    <nct_id>NCT04943107</nct_id>
  </id_info>
  <brief_title>Effect of Antihypertensive Drugs on Glaucoma Patients</brief_title>
  <official_title>Effect of Antihypertensive Drugs on Glaucoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been reported that among Asian non-glaucomatous, antihypertensive medications were&#xD;
      associated with retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness.&#xD;
      In order to explore whether antihypertensive medications would influence the neuropathy among&#xD;
      glaucomatous population, we designed a cross-sectional observational study to analyze the&#xD;
      retinal status among glaucoma patients with use of antihypertensive medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      we designed a cross-sectional obeservational study to analyze the retinal status among&#xD;
      glaucoma patients with use of hyertensive medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>retinal nerve fiber layer thickness</measure>
    <time_frame>within 3 months from recruitment</time_frame>
    <description>retinal nerve fiber layer thickness measured by optical coherence tomography</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
    <description>adults without glaucoma history or hypertension history</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glaucoma patients</arm_group_label>
    <description>adults with primary glaucoma history; without glaucoma-related operation history; without hypertension history</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertension patients</arm_group_label>
    <description>adults with primary hypertension history; without glaucoma history</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glaucoma+hypertension</arm_group_label>
    <description>adults with primary glaucoma history and primary hypertension history; without glaucoma-related operation history</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..</description>
    <arm_group_label>glaucoma patients</arm_group_label>
    <arm_group_label>glaucoma+hypertension</arm_group_label>
    <arm_group_label>healthy control</arm_group_label>
    <arm_group_label>hypertension patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        outpatient from ophthalmology and cardiology clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age no less than 18 years&#xD;
&#xD;
               -  best corrected visual acuity better than decimal 0.3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary glaucoma&#xD;
&#xD;
               -  secondary hypertension&#xD;
&#xD;
               -  glaucoma-related operation history&#xD;
&#xD;
               -  pregnancy or lactation period&#xD;
&#xD;
               -  uncooperative with retinal examination&#xD;
&#xD;
               -  severe opacity with refracting media in eye&#xD;
&#xD;
               -  severe retinal diseases and neuropathy&#xD;
&#xD;
               -  congenital retinal optic nerve abnormality&#xD;
&#xD;
               -  other systemic diseases that influence hypertension and glaucoma assessment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaijun Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of College of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kaijun Wang, MD</last_name>
    <phone>+86 13600529217</phone>
    <email>wkj992@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaijun Wand, MD</last_name>
      <phone>+86 1360052917</phone>
      <email>wkj992@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 27, 2021</last_update_submitted>
  <last_update_submitted_qc>June 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

